Evidence map›Paper›PMID 40145812›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

KK2DP7 Stimulates CD11b

Rui Zhang, Lin Tang, Yusi Wang, Xuejing Zhou, Zhenyu Ding, Li Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. CIITA/PRMT5 promote CD4BMC medicine · 2026
    Article
  2. Review
  3. Review
  4. KK2DP7 Stimulates CD11bAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rui ZhangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lin TangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yusi WangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xuejing ZhouDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhenyu DingDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Li YangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.ORCID https://orcid.org/0000-0002-7880-2113

Funding

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University ZYGD23008National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Z2023JC002National Key Research and Development Program of China 2023YFC3405200National Natural Science Foundation of China 82203033National Natural Science Foundation of China 82471854Sichuan Science and Technology Program 2023YFS00 01
6 · The paper itself

Abstract

The induction of trained immunity for anti-tumor therapy represents an emerging frontier in immunotherapy research, though its mechanistic underpinnings remain poorly understood. Adjuvant-induced trained innate immune responses constitute a critical yet underexplored component of adjuvant mechanisms of action. Here, KK2DP7, a dendrimer-structured peptide derived from the immunomodulatory antimicrobial peptide DP7 (VQWRIRVAVIRK) is employed, as a model adjuvant to establish standardized protocols for investigating adjuvant efficacy and mechanisms in enhancing anti-tumor immunity via trained immunity. Initial studies revealed that KK2DP7 administration significantly delayed tumor growth post-inoculation in murine models. The comprehensive analysis demonstrated that splenic cells exhibited cardinal features of trained immunity, whereas splenectomized mice exhibited complete loss of this protective effect. Strikingly, the adoptive transfer of CD11b

Indexed as

CD11b AntigenImmunity, InnateImmunotherapyNeoplasmsSpleenAnimalsFemaleMiceMice, Inbred C57BLTrained ImmunityCD11b Antigenanti‐tumor therapyCD11b+ cellscongenital immunitytraining immunitytumor immunotherapy

Identifiers

PMID40145812
PMCPMC12199376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.